NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) announced management will attend investor conferences in early March 2026, including TD Cowen (Boston, Mar 3), Leerink Partners (Miami, Mar 9) and Jefferies Biotech on the Beach (Miami Beach, Mar 10).

Presentations and a fireside chat will be webcast live via the company's investor relations site, with archived replays available after each event.

NAARDEN, the Netherlands and MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

• TD Cowen 46th Annual Health Care Conference in Boston, MA on Tuesday, March 3, 2026. Michael Davidson, M.D., Chief Executive Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will present a corporate overview at 10:30 a.m. ET on Tuesday, March 3.
• Leerink Partners Global Healthcare Conference 2026 in Miami, FL on Monday, March 9, 2026. Michael Davidson, M.D., Chief Executive Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 8:40 a.m. ET on Monday, March 9.
• Jefferies Biotech on the Beach Summit Miami Beach, FL on Tuesday, March 10, 2026. Company management will be available for 1x1 meetings throughout the day.
  

Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well-tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well-tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

When will NewAmsterdam Pharma (NAMS) present at the TD Cowen Health Care Conference in 2026?

NewAmsterdam will present at TD Cowen on Tuesday, March 3, 2026 at 10:30 a.m. ET. According to NewAmsterdam, CEO Michael Davidson, CFO Ian Somaiya and EVPI Matthew Philippe will deliver a corporate overview and participate in the live webcast.

How can investors watch NewAmsterdam Pharma's (NAMS) March 2026 presentations?

Investors can watch live webcasts via NewAmsterdam's investor relations site at ir.newamsterdampharma.com. According to NewAmsterdam, both live presentations will be streamed and archived replays will be posted after each event for on-demand viewing.

Who from NewAmsterdam Pharma (NAMS) will participate at the Leerink Partners Global Healthcare Conference on March 9, 2026?

CEO Michael Davidson, CFO Ian Somaiya and EVP Head of IR Matthew Philippe will participate in a fireside chat on March 9, 2026 at 8:40 a.m. ET. According to NewAmsterdam, the session will be available via the company's live webcast.

What is NewAmsterdam Pharma's (NAMS) schedule at Jefferies Biotech on the Beach Summit in March 2026?

NewAmsterdam management will be available for one-on-one investor meetings throughout Tuesday, March 10, 2026. According to NewAmsterdam, the team is scheduling 1x1 meetings and will not list a public presentation time for that day.

Will archived replays of NewAmsterdam Pharma (NAMS) March 2026 presentations be available after the events?

Yes, archived replays will be posted on NewAmsterdam's investor relations website after the live webcasts conclude. According to NewAmsterdam, investors can access the replays on ir.newamsterdampharma.com for later review and due diligence.

What topics will NewAmsterdam Pharma (NAMS) cover during its March 2026 investor presentations?

Presentations will provide a corporate overview and investor updates; a fireside chat is also scheduled. According to NewAmsterdam, management will discuss the company's clinical programs for oral, non-statin medicines and general corporate strategy during the webcasts.